ACD-856
This note is educational and is not personal medical advice. Effects vary by baseline status, dose, product quality, medications, sleep debt, diet, and health conditions.
Summary / What it does
ACD-856 is a negative allosteric modulator (NAM) of α5-subunit-containing GABA-A receptors. By reducing tonic inhibitory signaling in the hippocampus, it is theorized to enhance learning and memory through improved signal-to-noise in excitatory circuits. It is a very early-stage research compound with no human clinical data.
Useful cross-links: Glutamate, AMPA, NMDA Modulation, Neurotransmitter Balance. Its effects are best evaluated through the Acute & Instant Effects pattern rather than as a single isolated effect.
How it works in the brain (detailed scientific mechanisms)
α5-containing GABA-A receptors are concentrated in hippocampal dendrites, where they mediate tonic (persistent, extrasynaptic) inhibition. This tonic GABAergic tone acts as a background damping signal on pyramidal neurons, opposing the excitatory drive needed for LTP induction and memory encoding. By acting as a NAM at these receptors, ACD-856 reduces tonic inhibition without blocking phasic synaptic inhibition — theoretically sharpening hippocampal excitatory signals and improving LTP without widespread disinhibition and associated seizure risk.
This mechanism differs fundamentally from racetams (which potentiate AMPA) or acetylcholinesterase inhibitors (which increase ACh). ACD-856’s approach targets the balance point between excitation and inhibition at the circuit level. The precision of the α5 target is important: widespread GABA-A blockade causes anxiety and seizures, but α5-selective NAMs avoid those risks in preclinical models. Whether this selectivity translates to a clean human profile remains to be established.
Related mechanism notes: Glutamate, AMPA, NMDA Modulation, Neurotransmitter Balance.
Different variations/forms
Research compound only. No consumer-grade product form exists. Requires synthesis from a research chemical supplier and appropriate laboratory context.
Time to action / onset
Not established in humans. Preclinical pharmacokinetic profiles suggest potential acute onset, but no human data exists.
Half-life
Not established in humans.
Dosage
No established human dose exists. This compound should not be self-administered without professional oversight and appropriate research context.
Positive effects
Theoretical positive effects based on preclinical data include enhanced hippocampal LTP, improved memory encoding, better learning efficiency, and sharper cognitive signal-to-noise.
Reported Effects
No established human experience profile exists. Preclinical animal models demonstrated significant improvements in spatial and associative memory tasks with α5-NAM compounds.
Side effects / contraindications
Unknown in humans. Theoretical risks include anxiety, seizure liability at higher doses if selectivity is lost, and interaction with any other GABAergic medications. Contraindicated for use without appropriate medical oversight.
Where it is found in food or nature (natural sources)
ACD-856 is a fully synthetic research compound with no natural analogue.
Protocol
No protocol can be responsibly recommended. ACD-856 has no established human dosing, safety data, or approved clinical use. Do not self-administer.
Key Research
- Savić et al. (2005): Foundational work on α5-GABA-A NAMs demonstrated improved acquisition in contextual fear conditioning in mice without anxiogenic effects.
- Dawson et al. (2006): α5IA (a prototype α5-NAM) improved declarative memory in healthy human volunteers in a small crossover study — proof-of-concept for the class.
- Atack et al. (2006): Demonstrated α5-NAM selectivity profile and LTP enhancement in hippocampal slice preparations, establishing the mechanistic rationale for ACD-856-class compounds.
Forms & Sourcing
Research synthesis only. No retail product. Not approved for human use in any jurisdiction. Seek appropriate regulatory and institutional context before handling.
Other notes
ACD-856 represents an emerging class of cognition-enhancing GABA modulators targeting hippocampal α5 receptors. The most relevant neighboring compounds are Neboglamine (NMDA glycine-site) and BPN-14770 (PDE4D). All three share the theme of novel mechanistic targets for memory enhancement.
Related notes: BPN-14770, Neboglamine, Noopept, Racetams, Glutamate, AMPA, NMDA Modulation